Following last week’s launch, doctors are weighing TrumpRx, a federal government based prescription drug platform, for its potential to lower patient costs while noting its limitations.

The platform can be accessed at TrumpRx.gov and promises "large discounts on many of the most popular and highest-priced medicines in the country," according to the White House.

The goal is for consumers to get the lowest available pricing among other developed nations, referred to as the MFN price. This approach signals a move toward simpler, more transparent pricing that can empower patients rather than leaving them at the mercy of opaque billing.

As of its initial launch, TrumpRx includes discounted pricing for 40 medications from five pharmaceutical manufacturers: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer. That lineup signals a deliberate starting point rather than a broad catalog that covers every essential medicine.

Here's What They're Not Telling You About Your Retirement

Depending on the manufacturer of a given drug, patients with valid prescriptions will be able to access savings through user-friendly coupons that can be printed or downloaded onto their phones or through channels set up by the manufacturer and integrated into TrumpRx.gov, the announcement says.

This mechanism creates a straightforward path from the platform to real cash savings for patients.

TrumpRx is not an online pharmacy, as it does not directly prescribe, dispense or sell medications. It serves as a price comparison and discount tool that connects patients with coupons, manufacturer channels and sometimes GoodRx linked options.

Dr. Brett Osborn, a Florida neurosurgeon and longevity expert, called it a solid concept, putting cheaper, cash-pay drug prices at the forefront. "Prescription drugs are one of the quiet ways families get squeezed every month," he said.

This Could Be the Most Important Video Gun Owners Watch All Year

Marc Siegel, a senior medical analyst, described TrumpRx as a step in the right direction. "We have a lack of price transparency in the system — drugmakers and pharmacy benefit managers jack up the prices, which insurance companies pay, but then transfer the cost to the consumer in terms of higher premiums, copays and deductibles," Siegel said.

Siegel said the goal is not to enact government price controls but to increase consumer choices, allowing them to pay directly for drugs in amounts that do not exceed what other countries are paying. "TrumpRx will help provide access to crucial drugs that are otherwise not affordable or not covered by insurance, such as fertility drugs, cancer drugs, the growing GLP1 market, diabetes drugs and asthma drugs," Siegel said.

Even with discounts offered through TrumpRx or through its partnership with GoodRx, where you go from TrumpRx to an online pharmacy with a prescription or to the manufacturer, these drugs are still expensive. This first iteration of the marketplace focuses on anti obesity drugs like GLP1 agonists, although Osborn said that is exactly where national attention should be.

Obesity is not a cosmetic issue, it is a metabolic epidemic, a gateway disease that underpins heart disease, stroke, diabetes, certain cancers, dementia and massive downstream health spending, he said. On TrumpRx, injectable Ozempic and Wegovy could cost about $350 per month on average, down from $1,000 plus, with some doses as low as $199 per month.

The price for Zepbound, Eli Lilly’s obesity medication, could fall to about $346 per month on average, or as low as $299 depending on the dose. Commonly used medications for infertility, COPD, asthma, dermatitis, hot flashes and osteoporosis are also included.

Osborn commended the platform for "not trying to be everything."

"A more directed platform like TrumpRx that highlights medications that address ‘root cause’ diseases sends a MAHA signal," he said, "It shows people what matters."

Novo Nordisk, maker of Ozempic and Wegovy, applauded the launch of the platform. "We’re continuing to make it easier for people to access our authentic, FDA-approved medicines by expanding availability through multiple, convenient options," said Chris Pernie, associate vice president of U.S. public affairs, referencing NovoCare Pharmacy, the company’s direct-to-patient channel that launched in March 2025. "The launch of TrumpRx will further extend patients’ reach to Ozempic and Wegovy, including the newly approved Wegovy pill, at our self-pay prices," Pernie added in a statement.

Osborn cautioned that some drugs may not always be cheaper than insurance once deductibles are met. "Cash payments (accessed through the platform’s coupons) do not count toward out-of-pocket limits," he pointed out. "And comparing TrumpRx prices to list prices can make discounts on the site look bigger than they really are."

In a new commentary, Dr. Jeffrey Singer acknowledged that direct-to-consumer drug sales can help push prices down, but suggested that federal government’s control of the system could pose a risk. "President Trump is right that direct-to-consumer drug sales can restore cost sensitivity and put pressure on prices," Singer wrote. "But a government-run platform risks crowding out private competition and reintroducing political favoritism into a market that was already becoming more consumer-driven."

Siegel also pointed out that there is some concern about the impact on pharmaceutical research and development, "I am also concerned about more cheap copies spinning off here as a result, especially with the weight-loss drugs." As TrumpRx continues to evolve, Osborn recommends that antihypertensives should be added. "Blood pressure control is non-negotiable. Control blood pressure, blood sugar, lipids, body composition and lifestyle, and health follows," he said.

Health officials are working to secure more agreements with pharmaceutical companies to expand the selection of prescription drugs on the platform. "As the Trump administration pursues the best possible deals for the American people, additional high-cost medications will be added on a rolling basis," The White House’s announcement states.

Overall, Osborn said he believes TrumpRx could help to "flip the script" on the "death spiral of chronic disease management." "Lower drug costs should be seen as an American win — not a partisan one," he said. "This is a bid toward the center, not toward the right or the left. Although it is so right."